Lupin Subsidiary Acquires Majority Stake in Kaveri Therapeutics

🧬 $LUPIN announced that its subsidiary, Lupin Inc., has acquired an 82.2% equity stake in Kaveri Therapeutics. The transaction includes an exclusive license to two oncology programs and is valued at approximately US$1.6 million, strengthening the company's oncology pipeline.